The topic of this article may not meet Wikipedia's notability guideline for biographies. (February 2022) |
Véronique E. Miron is the John David Eaton Chair in Multiple Sclerosis Research at the Barlo MS Centre and Keenan Research Centre for Biomedical Science,[1] Full Professor at the University of Toronto Department of Immunology,[2] and Honorary Chair at the University of Edinburgh Dementia Research Institute.[3]
.jpg)
Education
editMiron received her B S. from McGill University in 2004, and her PhD in Neurological Sciences, also from McGill, with Prof Jack Antel in 2009. Her PhD thesis was on "The effects of CNS-accessible multiple sclerosis-directed immuno-modulatory therapies on oligodendroglial lineage cells, myelin maintenance, and remyelination".[4] She then carried out her postdoctoral studies at the Centre for Regeneration in Scotland, training under Prof Charles ffrench-Constant and Prof Robin Franklin.[5]
Research
editMiron conducts research on neuroimmunology,[6] specifically, how microglia support myelin formation and regeneration. Much of her work is related to neurological disorders such as multiple sclerosis. She is one of the ten Laureates of the 2020 Suffrage Life Science award for her scientific investigations.[7]
Most cited publications
edit- Miron VE, Boyd A, Zhao JW, Yuen TJ, Ruckh JM, Shadrach JL, van Wijngaarden P, Wagers AJ, Williams A, Franklin RJ. M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nature neuroscience. 2013 Sep;16(9):1211-8 to Google Scholar, it has been cited 1175 times.[8]
- Kuhlmann T, Miron V, Cuo Q, Wegner C, Antel J, Brück W. Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis. Brain. 2008 Jul 1;131(7):1749-58. According to Google Scholar, this article has been cited 691 times [8]
- Miron VE, Jung CG, Kim HJ, Kennedy TE, Soliven B, Antel JP. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Annals of Neurology 2008 Jan;63(1):61-71. According to Google Scholar, this article has been cited 275 times [8]
- Miron VE, Ludwin SK, Darlington PJ, Jarjour AA, Soliven B, Kennedy TE, Antel JP. Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices. The American journal of pathology. 2010 Jun 1;176(6):2682-94 According to Google Scholar, this article has been cited 257 times [8]
- Miron VE, Kuhlmann T, Antel JP. Cells of the oligodendroglial lineage, myelination, and remyelination. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2011 Feb 1;1812(2):184-93 According to Google Scholar, this article has been cited 250 times [8]
- Miron VE, Schubart A, Antel JP. Central nervous system-directed effects of FTY720 (fingolimod). Journal of the neurological sciences. 2008 Nov 15;274(1-2):13-7 According to Google Scholar, this article has been cited 179 times.[8]
- Miron VE, Franklin RJ. Macrophages and CNS remyelination. Journal of neurochemistry. 2014 Jul;130(2):165-71 [2] According to Google Scholar, this article has been cited 165 times [8]
References
edit- ^ "Professor Veronique Miron | Unity Health Toronto".
- ^ "Professor Veronique Miron | University of Toronto".
- ^ "Professor Veronique Miron | University of Edinburgh UK DRI".
- ^ "Index Catalog // EScholarship@McGill".
- ^ "Dr Veronique Miron".
- ^ "Veronique Miron".
- ^ "Awards 2020: Leading women in 'life sciences' and 'mathematics & computing' win award". 6 November 2020.
{{cite web}}: Missing or empty|url=(help) - ^ a b c d e f g [1] Google Scholar Author page, Accessed July 3, 2021
External links
edit- Veronique Miron's lab website
- Véronique Miron publications indexed by Google Scholar